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Diabetes is a common risk factor associated with coronary artery disease (CAD). Importantly, 
hereditary CAD cannot be discounted which accounts for about one quater of the cases [1]. 
Carotid artery disease (CARD) shares the same risk factors as CAD [2]. C-reactive protein 
and fibrinogen also contribute to the progression of atherosclerotic plaques, CAD and to the 
clinical outcome of patients with CAD and type-2 diabetes (T2D) [3]. Early detection and 
intervention of CAD in T2D patients is therefore important in order to improve better 
treatment and survival of high risk patients, although  recomendation is not high [4]. Despite 
many screening tests, there are a lack of studies that define factors for progression of 
coexistent CAD and T2D [5]. Herein, we assessed a potential value of carotid ultrasound in 
prognosis of patients with CAD and T2D.  
In this cohort study, 264 patients with CAD and T2D were included. They were 
consequently selected from CAD registry from the University Clinic of Cardiology, Skopje, 
Republic of Northern Macedonia. T2D was defined by criteria of the International Diabetes 
Federation. CAD was defined as stable angina, or previous myocardial infarction, detected 
with coronary  angiography. The study population had mean glycemia 8.5 ± 2.4 mmol/l, 
calculated Gensiini score 82.3 ± 18.4 and creatinin value of 102.5 ± 12.8 mmol/l. Basic 
characteristics of all patients are shown in Table 1. 94.1% of patients were on anti-agregation 
therapy and 85.9% on statins. Oral anti-diabetics were prescribed in 35.9 % (of which 39.4 % 
were on monotherapy with metformin), and insulin therapy in 58.2 % of the patients. Of all 
patients, 222 (84.1%) were on beta blockers and 219 (82.9%) were on ACE (angiotensin 
converting enzyme) inhibitors or ARB (angiotensin receptor blocators). Study population was 
followed up for 31.5 ± 10.4 months. Carotid ultrasound was used for detection of progression 
of CARD. And CAD in patients was confirmed with angiography. The study was conducted 
in accordance with the Helsinki declaration and was approved by the human ethics of the 
medical faculty Skopje. Carotid intima-media thickness (CIMT) was measured by B-mode 
ultrasound using a linear transducer (7.5-10 MHz) and was performed by experienced 
sonographers. CIMT is presented as a mean value of two measurements from both sides of 
the common carotid arteries. CIMT is defined as the distance from the leading edge of the 
first echogenic line to the leading edge of the second echogenic line on the scans. Plaque was 
defined as a localized thickening lesion (1.5 mm). Carotid stenosis greater than 60% was 
considered significant in accordance to the North American Symptomatic Carotid 
Endarterectomy Trial (NASCET) criteria for carotid stenosis. In each longitudinal projection, 
the site with the greatest thickness (including plaques) was detected along the vessel from the 
common carotid artery to the internal carotid artery. Inter-observer variability was up to 5%. 
 Patients were followed up in the outpatient clinic after phone interview for total 
cardiovascular events (stroke, new angina, myocardial infarction). New angina was defined 
as new typical onset of symptoms in previously stable patients as proposed by the European 
Society of Cardiology (ESC) Guidelines 2013; stroke by the World Health Organization 
Monica' criteria, and myocardial infarction by ESC guidelines 2017. 
Cohort follow-up showed that progression of CIMT was present in 86.8% of patients, 
progression of carotid stenosis in 17.8% and occurrence of plaques in 41.8% of these 
patients. In addition, the mean CIMT was 0.9176 mm and the maximal CIMT was 1.1212 
mm, and the maximal value of CIMT changed by 0.07 mm annually. New cardiovascular 
events were registered in 145 patients with incidence of 0.55 events per patient. The 
independent indicators of future cardiovascular events are presented in Table 2. The 
indicators being a change from the mean of IMT for occurrence of new angina [odds ratio 
(OR) 1.25, 95%; confidence interval (CI) 0.94-1.67; Gensini score > 70 (OR 1.91, 95% CI 
0.99-3.9)]. The progression of CIMT after being subjected to multivariate analysis did not 
show any significance regarding cardiovascular prognosis. This parameter has been shown to 
be a strong predictor for total cardiovascular events with OR 13.5 (95% CI 1.68-108.40). 
Carotid ultrasound is commonly used to measure CIMT and atherosclerotic plaques. 
However, the relationship to cardiovascular events is still controversial. In a systematic 
review, it was noted that for each change in CIMT of 0.1 mm, the risk of further coronary or 
cerebrovascular occurence was 10-30% higher compared to controls. In addition, a change of 
CIMT in patients with CAD of 0.03 mm in 1 year has a high risk rate of 2.2 for future 
coronary events. The use of mean maximum CIMT rather than mean common CIMT is the 
prefered factor used to determine the efficacy of drug interventions in carotid artery 
atherosclerosis. Drugs  such as statins or anti-hypertensives, aim at achieving stop of 
progression  of  CIMT and consequently it is expected that these would reflect on the rate of 
cardiovascular risk. Over 80% of our study population were taking anti-hypertensives or 
statins. A  proven separate role of CIMT for prognosis of T2D population with CAD is only 
obtained within a certain period of time. However, studies completed until now, show only 
the progression of coronary atherosclerosis in relation to the occurence of events in the 
general population and in those with T2D [6]. We noted an independent relationship between 
new angina and severity of CAD measured by Gensini score. Carotid artery disease and the 
change of CIMT, for a certain period of time, is preconditioned with the very same risk 
factors as those of CAD. It may explain the multipurpose prognostic role of  CIMT with  new 
coronary and cardiovascular events. On the other hand, the progression of carotid plaques 
have greater dynamics,  when compared to the progression of CIMT. Recent studies have 
shown that the combination of calcification length and plaque surface irregularity has 
additional value beyond the traditional risk classification towards coronary events [2, 3, 7]. 
However, there is still debate whether CIMT and its progression could be a surrogate marker 
for future events in patients with T2D. The reason for this is that the diabetic population is 
defined as high risk or very high risk if artery disease is presented. CARD was presented as 
an increase in CIMT, and presence of carotid plaques was an independent predictor for 10 
year coronary and stroke risk in T2D patients without known CAD [5]. As a result, the 
obtained risk factors can be suggested as surrogate markers when it comes to defining the 
process of progress of atherosclerosis with T2D and its connection with clinical outcome.     
Atherosclerotic plaque detection by carotid artery scaning have been defined as risk 
modifiers for individual risk stratification according to the European guidelines for 
cardiovascular prevention. The question is still open regarding the patient cohort with CAD 
and/or T2D. Atherosclerosis is a common feature for coronary and cerebrovascular disease. 
Hence, in this high risk population there is a connection between CAD and CARD.  
 However, there are studies which contradict this relationship. Indeed, in 120 patients 
with stroke, there was no connection between CARD scanned by CT and outcome of future 
coronary events [8]. In the MESA study [9], carotid plaques scanned by ultrasound imaging 
were related to progression of CAD. Other studies (ARIC, CAPS) showed tight correlation 
between CIMT and cardiovascular events (OR 1.2 to 1.3 for stroke and myocardial 
infarction) [9]. Thus, carotid plaques may be a more sensitive marker than CIMT for 
predicting risk of CAD [10]. Corelation between progression of carotid artery stenosis and 
cerebrovascular disease, has been previosly reported [5]. In a meta analysis study a link was 
reported between CIMT progression and cardiovascular events in the general population [11]. 
According to this  study, progression of the CARD appears to be much more indicative for 
future cerebrovascular events in patients with T2D. Our study, shows that the occurence of 
new carotid plaques is a strong indicator for the occurrence of all the cardiovascular events, 
included stroke, myocardial infarction and new angina. CIMT progression has been defined 
as a modest predictor for new angina. This study is limited in that it did not include many 
participants, which were non-randomly selected. Other limitations to the current study is the 
point for follow up: new angina, without diagnostic evidence for new ischemia, and 
information for new coronary revascularization. The advantages of our study is that it defines 
progression of CARD in predicting outcome due to a coronary and cardiovascular events in 
patients with very high risk i.e those with T2D and CAD.  
The current study determined the factors which indicate the progression of 
atherosclerosis in a population cohort with Т2D. Clinical implications of our study comes 
from defining progression of CARD to predict outcome due to coronary and cardiovascular 
events in a population cohort with T2D. In this predictive model for patients with T2D and 
CAD, carotid ultrasound has been shown to be of incremental value.   
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